These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1385995)

  • 1. Plasma beta-endorphin is not affected by treatment with imipramine or paroxetine in patients with diabetic neuropathy symptoms.
    Sindrup SH; Bach FW; Gram LF
    Clin J Pain; 1992 Jun; 8(2):145-8. PubMed ID: 1385995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms.
    Sindrup SH; Gram LF; Brøsen K; Eshøj O; Mogensen EF
    Pain; 1990 Aug; 42(2):135-144. PubMed ID: 2147235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of paroxetine, imipramine and placebo in depressed out-patients.
    Dunbar GC; Cohn JB; Fabre LF; Feighner JP; Fieve RR; Mendels J; Shrivastava RK
    Br J Psychiatry; 1991 Sep; 159():394-8. PubMed ID: 1835664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A placebo- and imipramine-controlled study of paroxetine.
    Cohn JB; Crowder JE; Wilcox CS; Ryan PJ
    Psychopharmacol Bull; 1990; 26(2):185-9. PubMed ID: 2146697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lidocaine treatment of painful diabetic neuropathy and endogenous opioid peptides in plasma.
    Kastrup J; Bach FW; Petersen P; Dejgård A; Ekman R; Jensen S; Angelo H
    Clin J Pain; 1989 Sep; 5(3):239-44. PubMed ID: 2577686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paroxetine and imipramine treatment of depressive patients in a controlled multicentre study with plasma amino acid measurements.
    Nielsen OA; Morsing I; Petersen JS; Larsen T; Møller SE; Manniche PM; Skausig OB
    Acta Psychiatr Scand; 1991 Sep; 84(3):233-41. PubMed ID: 1835251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paroxetine in major depression: a double-blind trial with imipramine and placebo.
    Cohn JB; Wilcox CS
    J Clin Psychiatry; 1992 Feb; 53 Suppl():52-6. PubMed ID: 1531826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imipramine treatment of painful diabetic neuropathy.
    Kvinesdal B; Molin J; Frøland A; Gram LF
    JAMA; 1984 Apr; 251(13):1727-30. PubMed ID: 6366276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of effect of mianserin on the symptoms of diabetic neuropathy.
    Sindrup SH; Tuxen C; Gram LF; Grodum E; Skjold T; Brøsen K; Beck-Nielsen H
    Eur J Clin Pharmacol; 1992; 43(3):251-5. PubMed ID: 1425887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function.
    Sindrup SH; Ejlertsen B; Frøland A; Sindrup EH; Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1989; 37(2):151-3. PubMed ID: 2792168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The short- and long-term efficacy of paroxetine HCl: B. Data from a double-blind crossover study and from a year-long term trial vs. imipramine and placebo.
    Peselow ED; Filippi AM; Goodnick P; Barouche F; Fieve RR
    Psychopharmacol Bull; 1989; 25(2):272-6. PubMed ID: 2532374
    [No Abstract]   [Full Text] [Related]  

  • 12. A double-blind comparison of paroxetine, imipramine, and placebo in major depression.
    Shrivastava RK; Shrivastava SH; Overweg N; Blumhardt CL
    J Clin Psychiatry; 1992 Feb; 53 Suppl():48-51. PubMed ID: 1531825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients.
    Fabre LF
    J Clin Psychiatry; 1992 Feb; 53 Suppl():40-3. PubMed ID: 1531823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy.
    Lauritzen L; Odgaard K; Clemmesen L; Lunde M; Ohrström J; Black C; Bech P
    Acta Psychiatr Scand; 1996 Oct; 94(4):241-51. PubMed ID: 8911559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxetine in the treatment of depression: a comparison with imipramine and placebo.
    Feighner JP; Boyer WF
    J Clin Psychiatry; 1992 Feb; 53 Suppl():44-7. PubMed ID: 1531824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms.
    Sindrup SH; Gram LF; Skjold T; Frøland A; Beck-Nielsen H
    Clin Pharmacol Ther; 1990 Apr; 47(4):509-15. PubMed ID: 2328559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concentration-response relationship in paroxetine treatment of diabetic neuropathy symptoms: a patient-blinded dose-escalation study.
    Sindrup SH; Grodum E; Gram LF; Beck-Nielsen H
    Ther Drug Monit; 1991 Sep; 13(5):408-14. PubMed ID: 1835549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The short- and long-term efficacy of paroxetine HCl: A. Data from a 6-week double-blind parallel design trial vs. imipramine and placebo.
    Peselow ED; Filippi AM; Goodnick P; Barouche F; Fieve RR
    Psychopharmacol Bull; 1989; 25(2):267-71. PubMed ID: 2532373
    [No Abstract]   [Full Text] [Related]  

  • 19. A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression.
    Claghorn JL; Feighner JP
    J Clin Psychopharmacol; 1993 Dec; 13(6 Suppl 2):23S-27S. PubMed ID: 8106652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pain relief in diabetic neuropathy: the effectiveness of imipramine and related drugs.
    Young RJ; Clarke BF
    Diabet Med; 1985 Sep; 2(5):363-6. PubMed ID: 2435449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.